[Federal Register Volume 60, Number 16 (Wednesday, January 25, 1995)]
[Notices]
[Page 4920]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-1805]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Committee on Immunization Practices; Meeting
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following committee meeting:
Name: Advisory Committee on Immunization Practices.
Times and Dates: 8:30 a.m.-6:30 p.m., February 9, 1995. 8:15
a.m.-4:45 p.m., February 10, 1995.
Place: CDC, Auditorium A, Building 2, 1600 Clifton Road, NE,
Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
Purpose: The committee is charged with advising the Director,
CDC, on the appropriate uses of immunizing agents.
Matters to be Discussed: The committee will discuss
recommendations for prevention of hepatitis A: Hepatitis A vaccine
and immune globulin; revised recommendations for hepatitis B
vaccination; update on varicella vaccine; status on principles and
guidelines for combination products; vaccines for children (VFC):
influenza vaccine in VFC, hepatitis B for adolescents in VFC,
hepatitis A, MMR2--expanded use in VFC; pneumococcal polysaccharide
vaccine; adolescent vaccination; poliomyelitis prevention;
influenza: 1995-96 influenza vaccine strain selection, 1995-96
influenza vaccine and antiviral recommendations, influenza-
associated morbidity during pregnancy, assessment of BBS risk
associated with 1993-94 and 1994-95 influenza vaccination, optimal
needle length for intramuscular injection into the deltoid, national
estimates of influenza vaccination rates; update on meningococcal
recommendation; report of a meeting regarding conflicting
immunization guidelines and harmonization of the Advisory Committee
on Immunization Practices/American Academy of Pediatrics
recommendations with the Food and Drug Administration labeling;
update on simplification; progress towards 1996 disease reduction
goals; recommendations for immunization linkage with the women's,
infants, and children program; vaccine safety; an update on the
Injury Compensation Program; an update on the National Vaccine
Program; and a presentation on acellular pertussis. Other matters of
relevance among the committee's objectives may be discussed.
Agenda items are subject to change as priorities dictate.
For Further Information Contact: Gloria A. Kovach, Committee
Management Specialist, CDC (1-B72), 1600 Clifton Road, NE., Mailstop
A20, Atlanta, Georgia 30333, telephone 404/639-3851.
Dated: January 18, 1995.
William H. Gimson,
Acting Associate Director for Policy Coordination, Centers for Disease
Control and Prevention (CDC).
[FR Doc. 95-1805 Filed 1-24-95; 8:45 am]
BILLING CODE 4163-18-M
